Related Experiment Video

Updated: Jan 18, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.9K

Effects of intensive rosuvastatin on ventricular remodeling and cardiac function in elderly patients with STEMI

Yiran Qin1, Siyi Jin2, Xusen Sun1

  • 1Department of Cardiology, Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University, Shanghai, China.

Frontiers in Cardiovascular Medicine
|September 8, 2025
PubMed

Insights

Intensive rosuvastatin therapy significantly improved cardiac function and reduced inflammation and ventricular remodeling in elderly STEMI patients post-PCI. High-dose rosuvastatin offers superior benefits for these patients.

Area of Science:

  • Cardiology
  • Pharmacology
  • Biomedical Engineering

Background:

  • Acute myocardial infarction (AMI) in the elderly frequently causes left ventricular (LV) remodeling, impacting prognosis.
  • ST-segment elevation myocardial infarction (STEMI) is a critical form of AMI requiring timely intervention.
  • Percutaneous coronary intervention (PCI) is a standard treatment for STEMI.

Purpose of the Study:

  • To assess the impact of intensive rosuvastatin therapy on ventricular remodeling markers.
  • To evaluate effects on cardiac function in elderly STEMI patients after PCI.
  • To compare high-dose versus standard-dose rosuvastatin efficacy.

Main Methods:

  • 100 elderly STEMI patients undergoing emergency PCI were randomized.
  • Intensive group (n=50) received rosuvastatin 20 mg/day; control group (n=50) received 10 mg/day.
  • Evaluated lipid profiles, inflammatory markers, fibrosis indicators, and echocardiographic parameters over 8 weeks.

Main Results:

  • Intensive rosuvastatin significantly reduced inflammatory markers (CRP, IL-6, TNF-α, ICAM-1).
  • Improved ventricular remodeling markers (lower NT-proBNP, galectin-3, MMP-9; higher TIMP-4).
  • Enhanced cardiac function (higher LVEF, stroke volume, TDI s'-l; lower LVESD, LVESV).

Conclusions:

  • High-dose rosuvastatin therapy is more effective than standard-dose in elderly STEMI patients post-PCI.
  • Intensive therapy alleviates inflammation, improves LV remodeling, and enhances cardiac function.
  • Rosuvastatin therapy positively impacts prognosis in this patient cohort.
Abstract

Keywords:
ST-segment elevation myocardial infarctioncardiac functioninflammatory cytokinesrosuvastatinventricular remodeling

More Related Videos

Author Spotlight: Enhancing Coronary Artery Revascularization05:25

Author Spotlight: Enhancing Coronary Artery Revascularization

Published on: September 15, 2023

1.2K
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.0K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
943
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
220
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
215
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
219
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
322
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
472